FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Retains Buy Rating On Steris Plc

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We maintain our 12-month target price at $275, based on 22.7x our new FY 28 EPS forecast, below STE's five-year average forward P/E multiple of 24.2x We keep our FY 27 EPS view at $11.22, which stands above the midpoint of the newly initiated guidance range of $11.10-$11.30, representing a solid 9%-11% Y/Y growth. We start our 2028 EPS estimate at $12.09. STE reported a solid close to its fiscal year 2026, characterized by robust revenue and earnings growth. For FY 26, the company posted a solid 9% Y/Y increase in revenue and adjusted earnings per share grew to $10.17 from $9.22. We expect this solid momentum to carry into FY 27 with 8% Y/Y top-line sales growth amid a more complex operating environment with broad-based growth across the three segments as we see healthy demand. Procedure volumes growth is a key driver for the company, and we see solid growth for the fiscal year ahead, supporting demand for STE's products and services catered for patient care and infection prevention.

Related Articles

Research

Research Alert: CFRA Maintains Sell Rating On Shares Of Dxc Technology Company

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We cut our price target to $7 from $11, 3x our FY 27 (Mar.) EPS view, a deep discount to peers on DXC's high leverage and sales declines and below its three-year average (~5.6x) on elevated macro uncertainty and rising AI competition. We lower our FY 27 view by $0.63 to $2.43 and set FY 28 at $2.28. We see DXC as far behind peers competitively, demonstrated most clearly in Q4 FY 26 via (1) a 13.5% Y/Y bookings decline, similar to recent weakness, (2) a lower than expected win-rate during the quarter(32%) for DXC's $2B large deal pipeline, and (3) a 9% guidance miss for FY 27 FCF (~$600M, down 16% Y/Y). We expect an uncertain macro throughout FY 27 to continue extending client decision making timelines, especially in Europe and the U.K. (49% of Q4 sales combined) as the war in Iran brings higher energy prices, further pressuring bookings. DXC's AI products do not appear to be gaining traction at peers' rates, making the company look more vulnerable to fears of AI-based competition in the services space.

$DXC
Research

Research Alert: CFRA Keeps Hold Opinion On Shares Of The Aes Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target is unchanged at $16, 6.5x our 2027 EPS estimate of $2.39, a significant discount to AES's five-year forward average of 10.3x and peer valuations. We note that our target sits above the $15.00 per-share deal price, and we maintain Hold, as we see limited upside beyond the offer while acknowledging some risk that the transaction may not close on current terms. Should the deal close as expected in late 2026 or early 2027, shareholders would receive $15.00 in cash; our modestly higher target reflects residual optionality around a potential price bump or deal failure that could re-rate shares. We lower both our 2026 and 2027 EPS estimates by $0.01 to $2.29 and $2.39, respectively. We expect revenue growth of approximately 4.2% in 2026, reflecting contributions from new renewables projects as AES works through its project backlog. We anticipate an adjusted EBITDA margin near 24% in 2026 compared to approximately 23.5% in 2025.

$AES
Research

K92 Mining Maintained at Buy at Stifel Canada Following Q1 Results; Price Target Kept at C$39.00

Stifel Canada on Tuesday reiterated its buy rating on the shares of K92 Mining (KNT.TO) and its C$39.00 price target after the Papua New Guinea miner released its first-quarter results."KNT reported Q1/26 adjusted EPS of $0.47 vs. our $0.43 (consensus $0.41) and EBITDA of $179.9Mln vs. our $169.0Mln (consensus $168.6Mln) on pre-released GEO production of 46.7Koz (44.0Koz Au + 1.70Mln lbs Cu + 38.8Koz Ag). Q1/26 EBITDA and EPS beat on higher GEO sales and lower exploration and tax expenses. Q1/26 cash cost of $785/oz (+13% vs. consensus $693/oz) and AISC of $1,421/oz, were above the FY26 guidance range reflecting higher operating costs during Stage 3 ramp up and lower gold head grade of 10.2g/t, partially offset by higher by-product credits. FY26 guidance was reiterated (GEO production of 190-225Koz at a cash cost $710-770/oz and AISC $1,250-1,350/oz) with production weighted to H2/26 from two new mining fronts and completion of expansion enablers. Stage 4 Expansion ventilation electrification is scheduled for mid-2026; and paste-fill practical completion is on track for Q4/26 with final commissioning in Q1/27," analyst Ralph Profiti wrote.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $27.84, Change: $+0.32, Percent Change: +1.16%

$KNT.TO